{"id":"https://openalex.org/W7210677192","doi":null,"title":"\u00c1cido bempedoico na dislipidemia: evid\u00eancia cl\u00ednica, considera\u00e7\u00f5es econ\u00f3micas e papel terap\u00eautico atual","display_name":"\u00c1cido bempedoico na dislipidemia: evid\u00eancia cl\u00ednica, considera\u00e7\u00f5es econ\u00f3micas e papel terap\u00eautico atual","publication_year":2026,"publication_date":"2026-07-31","ids":{"openalex":"https://openalex.org/W7210677192"},"language":"pt","primary_location":{"id":"pmh:oai:ojs.actafarmaceuticaportuguesa.com:article/494","doi":null,"is_oa":true,"landing_page_url":"https://actafarmaceuticaportuguesa.com/index.php/afp/article/view/494","pdf_url":"https://actafarmaceuticaportuguesa.com/index.php/afp/article/download/494/348","source":{"id":"https://openalex.org/S4306402433","display_name":"Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"2182-3340","raw_type":"journal article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://actafarmaceuticaportuguesa.com/index.php/afp/article/download/494/348","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5079137354","display_name":"\u00c3ngela Guimar\u00c3es","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Guimar\u00e3es, \u00c2ngela","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5150446158","display_name":"Margarida Marinho Alves","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Marinho Alves, Margarida","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.6457624,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11618","display_name":"Cholesterol and Lipid Metabolism","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1303","display_name":"Biochemistry"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12465","display_name":"Cancer, Lipids, and Metabolism","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/bempedoic-acid","display_name":"bempedoic acid","score":1.0},{"id":"https://openalex.org/keywords/dyslipidemia","display_name":"dyslipidemia","score":0.8679999709129333},{"id":"https://openalex.org/keywords/ldl-cholesterol-lowering","display_name":"LDL cholesterol lowering","score":0.8569999933242798},{"id":"https://openalex.org/keywords/statin-intolerance","display_name":"statin intolerance","score":0.828000009059906},{"id":"https://openalex.org/keywords/atp-citrate-lyase-inhibition","display_name":"ATP-citrate lyase inhibition","score":0.968999981880188},{"id":"https://openalex.org/keywords/major-adverse-cardiovascular-events","display_name":"major adverse cardiovascular events","score":0.9380000233650208},{"id":"https://openalex.org/keywords/lipid-lowering-therapy","display_name":"lipid-lowering therapy","score":0.8259999752044678},{"id":"https://openalex.org/keywords/cardiovascular-risk","display_name":"cardiovascular risk","score":0.6570000052452087},{"id":"https://openalex.org/keywords/drug-costs","display_name":"drug costs","score":0.703000009059906},{"id":"https://openalex.org/keywords/portugal","display_name":"Portugal","score":0.33899998664855957}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8180999755859375},{"id":"https://openalex.org/C2776839432","wikidata":"https://www.wikidata.org/wiki/Q954845","display_name":"Statin","level":2,"score":0.6197999715805054},{"id":"https://openalex.org/C2909478654","wikidata":"https://www.wikidata.org/wiki/Q844935","display_name":"Atherosclerotic cardiovascular disease","level":3,"score":0.5601999759674072},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.5552999973297119},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5486999750137329},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.4830999970436096},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.4666999876499176},{"id":"https://openalex.org/C3020000205","wikidata":"https://www.wikidata.org/wiki/Q2412849","display_name":"Narrative review","level":2,"score":0.3944999873638153},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.35580000281333923},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.3553999960422516},{"id":"https://openalex.org/C2778163477","wikidata":"https://www.wikidata.org/wiki/Q43656","display_name":"Cholesterol","level":2,"score":0.34929999709129333},{"id":"https://openalex.org/C140608501","wikidata":"https://www.wikidata.org/wiki/Q7318358","display_name":"Review article","level":2,"score":0.34599998593330383},{"id":"https://openalex.org/C2993857929","wikidata":"https://www.wikidata.org/wiki/Q1773974","display_name":"Primary prevention","level":3,"score":0.3319999873638153},{"id":"https://openalex.org/C2778384578","wikidata":"https://www.wikidata.org/wiki/Q16930687","display_name":"Therapeutic approach","level":3,"score":0.3199000060558319},{"id":"https://openalex.org/C50440223","wikidata":"https://www.wikidata.org/wiki/Q1475848","display_name":"Risk factor","level":2,"score":0.3075000047683716},{"id":"https://openalex.org/C3018906752","wikidata":"https://www.wikidata.org/wiki/Q844935","display_name":"Coronary heart disease","level":2,"score":0.3061999976634979},{"id":"https://openalex.org/C89611455","wikidata":"https://www.wikidata.org/wiki/Q6804646","display_name":"Mechanism (biology)","level":2,"score":0.30219998955726624},{"id":"https://openalex.org/C60644358","wikidata":"https://www.wikidata.org/wiki/Q128570","display_name":"Bioinformatics","level":1,"score":0.2962000072002411},{"id":"https://openalex.org/C3018284874","wikidata":"https://www.wikidata.org/wiki/Q389735","display_name":"Cardiovascular health","level":3,"score":0.27810001373291016},{"id":"https://openalex.org/C198082294","wikidata":"https://www.wikidata.org/wiki/Q3399648","display_name":"Position (finance)","level":2,"score":0.26910001039505005},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.265500009059906},{"id":"https://openalex.org/C3019550498","wikidata":"https://www.wikidata.org/wiki/Q28749","display_name":"Ldl cholesterol","level":3,"score":0.26330000162124634},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.2630000114440918},{"id":"https://openalex.org/C164705383","wikidata":"https://www.wikidata.org/wiki/Q10379","display_name":"Cardiology","level":1,"score":0.25870001316070557}],"mesh":[],"locations_count":1,"locations":[{"id":"pmh:oai:ojs.actafarmaceuticaportuguesa.com:article/494","doi":null,"is_oa":true,"landing_page_url":"https://actafarmaceuticaportuguesa.com/index.php/afp/article/view/494","pdf_url":"https://actafarmaceuticaportuguesa.com/index.php/afp/article/download/494/348","source":{"id":"https://openalex.org/S4306402433","display_name":"Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"2182-3340","raw_type":"journal article"}],"best_oa_location":{"id":"pmh:oai:ojs.actafarmaceuticaportuguesa.com:article/494","doi":null,"is_oa":true,"landing_page_url":"https://actafarmaceuticaportuguesa.com/index.php/afp/article/view/494","pdf_url":"https://actafarmaceuticaportuguesa.com/index.php/afp/article/download/494/348","source":{"id":"https://openalex.org/S4306402433","display_name":"Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"2182-3340","raw_type":"journal article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7210677192.pdf","grobid_xml":"https://content.openalex.org/works/W7210677192.grobid-xml"},"referenced_works_count":19,"referenced_works":["https://openalex.org/W2040713479","https://openalex.org/W2047207059","https://openalex.org/W2558991743","https://openalex.org/W2909249787","https://openalex.org/W2958980850","https://openalex.org/W2960191339","https://openalex.org/W3041939555","https://openalex.org/W3195110684","https://openalex.org/W4205325284","https://openalex.org/W4243807093","https://openalex.org/W4281261930","https://openalex.org/W4284974802","https://openalex.org/W4319293734","https://openalex.org/W4323075797","https://openalex.org/W4381888526","https://openalex.org/W4383302529","https://openalex.org/W4391187577","https://openalex.org/W4400390751","https://openalex.org/W4403844736"],"related_works":["https://openalex.org/W4411278244","https://openalex.org/W3080449802","https://openalex.org/W4389613637","https://openalex.org/W4323308814","https://openalex.org/W4389169867","https://openalex.org/W3119793469","https://openalex.org/W4387106271","https://openalex.org/W4402945015","https://openalex.org/W3195110684","https://openalex.org/W7213883832"],"abstract_inverted_index":{"Introduction:":[0],"Dyslipidaemia":[1],"is":[2,103],"one":[3],"of":[4,29,44,55,92,119,207,221,252],"the":[5,27,37,56,88,219,232,250],"main":[6],"modifiable":[7],"risk":[8,47,235],"factors":[9],"for":[10,191,218],"atherosclerotic":[11],"cardiovascular":[12,24,46,169,177,181,211,234,283],"disease,":[13],"with":[14,134,152,157,175,199],"LDL":[15,120],"cholesterol":[16,113],"(LDL-C)":[17],"remaining":[18],"a":[19,164,187,215],"central":[20],"therapeutic":[21,39,189,237,263],"target":[22],"in":[23,42,62,95,122,132,145,166,172,249,268],"prevention.":[25],"Despite":[26],"efficacy":[28],"available":[30],"lipid-lowering":[31,93,222,257],"therapies,":[32],"many":[33],"patients":[34,133,174,192],"remain":[35],"above":[36],"recommended":[38,276],"targets,":[40],"particularly":[41,130],"settings":[43],"high":[45,180],"or":[48,179,197,274],"statin":[49,137,200],"intolerance.":[50,201],"Method:":[51],"A":[52],"narrative":[53],"review":[54],"literature":[57],"was":[58],"conducted":[59],"through":[60],"searches":[61],"PubMed,":[63],"ScienceDirect":[64],"and":[65,76,83,90,115,150,209,239,259],"SciELO.":[66],"The":[67,159],"bibliographic":[68],"selection":[69],"prioritized":[70],"international":[71],"guidelines,":[72],"clinical":[73,269],"trials,":[74],"reviews":[75],"regulatory":[77],"documents":[78],"related":[79],"to":[80,136,231,255],"bempedoic":[81,278],"acid":[82,102,185,244],"dyslipidaemia":[84],"therapy.":[85,223],"Data":[86],"on":[87],"availability":[89],"costs":[91],"drugs":[94],"Portugal":[96],"were":[97],"also":[98],"included.":[99],"Results:":[100],"Bempedoic":[101,184,243],"an":[104,246,261],"oral":[105,203],"drug":[106],"that":[107,265],"inhibits":[108],"ATP-citrate":[109],"lyase,":[110],"reducing":[111],"hepatic":[112,126],"synthesis":[114],"promoting":[116],"increased":[117],"expression":[118],"receptors":[121],"hepatocytes.":[123],"Its":[124,202],"predominantly":[125],"activation":[127],"makes":[128],"it":[129,214],"relevant":[131,188],"limitations":[135],"use.":[138],"Clinical":[139],"trials":[140],"have":[141],"demonstrated":[142,163,210],"consistent":[143],"reductions":[144,154],"LDL-C,":[146,281],"generally":[147],"between":[148],"15%":[149],"25%,":[151],"greater":[153],"when":[155],"combined":[156],"ezetimibe.":[158],"CLEAR":[160],"Outcomes":[161],"trial":[162],"reduction":[165,196],"major":[167],"adverse":[168],"events":[170],"(MACE)":[171],"statin-intolerant":[173],"established":[176],"disease":[178],"risk.":[182,284],"Discussion:":[183],"represents":[186],"option":[190,217],"requiring":[193],"additional":[194],"LDL-C":[195],"presenting":[198],"administration,":[204],"complementary":[205],"mechanism":[206],"action":[208],"benefit":[212],"make":[213],"valuable":[216],"individualisation":[220],"However,":[224],"its":[225],"positioning":[226],"should":[227],"be":[228],"defined":[229],"according":[230],"patient\u2019s":[233],"profile,":[236],"targets":[238],"individual":[240],"characteristics.":[241],"Conclusion:":[242],"occupies":[245],"intermediate":[247],"position":[248],"management":[251],"dyslipidaemia,":[253,280],"helping":[254],"individualise":[256],"therapy":[258],"address":[260],"important":[262],"gap":[264],"remains":[266],"present":[267],"practice,":[270],"without":[271],"replacing":[272],"statins":[273],"other":[275],"therapies.Keywords:":[277],"acid,":[279],"statins,":[282]},"counts_by_year":[],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2026-09-07T00:00:00"}